

# Revolutionizing Early DILI Prediction

## AI-driven innovation for safer drug development

Certara Libra is transforming how researchers predict drug-induced liver injury (DILI), a critical challenge in drug development. By combining leading-edge AI with Certara's expertise, Libra accelerates decision-making and reduces risk with unmatched precision and speed.

## Key features

### Advanced QSAR modeling


Utilize advanced quantitative structure-activity relationship (QSAR) modeling to rapidly flag-up DILI hazard and drive smarter pipeline decisions.

### Bayesian predictive capability

Integrate physiochemical and in vitro assay data using a Bayesian machine learning model for advanced insights into potential DILI risks.

### Tailored, actionable outputs

Receive clear, customizable results designed to enhance decision-making and seamlessly fit into your workflow.



With an intuitive interface and advanced QSAR model, Libra optimizes early DILI predictions, transforming preclinical safety assessments.

## Why Libra?

Libra goes beyond traditional tools by offering an integrated approach within Certara's ToxStudio® suite of New Approach Methodologies (NAMs), alongside platforms like Cardiac Safety Simulator™ and Secondary Intelligence™. This NAM ecosystem solidifies Certara's leadership in modernizing preclinical safety assessments. Between them, these tools address three of the 'big ticket items' in preclinical safety: QT, off-target safety, and DILI. And there is more to come.

## Key benefits of Libra

- **High predictive accuracy**  
Achieve up to 85% accuracy in forecasting DILI risk, reducing failures at all stages of drug discovery and development.
- **Accelerated development timelines**  
Save time and resources by identifying high-risk candidates earlier in your pipeline.
- **Ethical and sustainable practices**  
Minimize reliance on in vivo studies while maintaining scientifically robust safety data.

## Integrated preclinical expertise

Libra is more than a product—it's a catalyst for transformation in drug development. By applying machine learning:

- Navigate complex safety challenges confidently.
- Enhance collaboration across teams with transparent, actionable insights.
- Stay ahead with a platform designed to complement your existing workflows without disruption.

---

Contact us today to learn how Libra can integrate seamlessly into your preclinical workflows.

---

### About Certara

Certara accelerates medicines using biosimulation software, technology, and services to transform traditional drug discovery and development. Its clients include more than 2,400 biopharmaceutical companies, academic institutions, and regulatory agencies across 70 countries.

Visit [certara.com](https://certara.com) | Copyright ©2025 Certara. All rights reserved.

## A sustainable approach

Innovation today must meet tomorrow's ethical standards. Libra reduces reliance on animal testing while delivering fast, precise safety insights. By aligning with evolving regulatory expectations, it ensures your development process stays ahead of the curve.

## Collaborative and future-forward

Libra fosters seamless integration between toxicology, drug discovery, medicinal chemistry, regulatory and translational science teams by providing a shared foundation of actionable data. This approach not only optimizes communication but accelerates progress, enabling milestones to be achieved with confidence.

## Why choose Certara

Certara's solutions have contributed to 90% of recent FDA drug approvals. With Libra, you benefit from the same pioneering approach, combining science, technology, and innovation to redefine drug development.

- **Expertly validated tools**  
Trusted by top pharmaceutical companies and regulators worldwide.
- **Proven impact**  
Drive better decisions through accurate, data-rich insights at every stage of your pipeline.
- **A partner in progress**  
Certara's team of experts supports your success at every step.

[Learn more](#)